31 providers urge Burwell to rethink MU

A letter to Department of Health and Human Services Secretary Sylvia Burwell from 31 healthcare organizations addresses concerns about Meaningful Use (MU) and the current state of EHRs.

Now that EHR adoption has largely been achieved, “we must turn our attention to ensuring that all of the practices in our respective communities have high-functioning technology to achieve interoperability across all care settings,” the letter reads.

Stage 3 could hinder those efforts, however. It is too focused on pass-fail requirements and lacks emphasis on outcomes so does not support movement toward more innovative care models or encourage continued participation, they wrote.

Stage 3 also doesn’t prioritize the improvement of interoperability, they say. MU’s enforcement aspects have not led to significant improvement in data exchange.

Because of these concerns, “we urge you to reconsider Stage 3 and refocus the administration’s efforts on the infrastructure needed to promote adoption, enhance interoperability and improve usability,” the letter reads. “We are of the collective mindset that this is an opportunity to improve the current trajectory of EHRs and the MU program to best support technical innovations and outcomes-based care. Navigating the digital landscape is a constant learning process.”

The letter was signed by leading healthcare providers including Weill Cornell Medicine, Vanderbilt University Medical Center and Partners HealthCare.

Beth Walsh,

Editor

Editor Beth earned a bachelor’s degree in journalism and master’s in health communication. She has worked in hospital, academic and publishing settings over the past 20 years. Beth joined TriMed in 2005, as editor of CMIO and Clinical Innovation + Technology. When not covering all things related to health IT, she spends time with her husband and three children.

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.